Investor Presentaiton slide image

Investor Presentaiton

Investor Presentation First six months of 2018. Slide 93 NovoEight® volumes continue to grow despite increasing penetration of long-acting FVIII products Novo Eight® roll-out continues and the number of patients has steadily increased Estimated number of patients¹ 2,500 Number of launch countries Number of patients 2,000 1,500 1,000 33 28 25 500 16 8 2014 2015 2016 2017 2018 2 Novo Eight® has potential to increase volume share in select segments and markets Competitive positioning for NovoEight® • • • Temperature stability at high room temperature and best-in- class portability Uptake driven by Novo Nordisk's strong customer focus and company recognition within the haemophilia community Continued volume growth especially in less mature markets with tender opportunities, despite increasing penetration of long-acting FVIII products Next generation . Global roll-out of NovoEight® and N8-GP to pave the way for subcutaneous N8-GP 1 Novo Nordisk estimated accumulated patient number 2 Novo Nordisk estimated accumulated patient number as of March 2018 FVIII: Coagulation factor VIII novo nordisk
View entire presentation